X4 Pharmaceuticals (XFOR) Reports Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to X4 Pharmaceuticals (XFOR) Reports Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia
(NASDAQ: XFOR) Delayed: 4.00 +0.12 (3.09%)
Previous Close $3.88    52 Week High $ 
Open $3.93    52 Week Low $ 
Day High $4.02    P/E N/A 
Day Low $3.90    EPS $ 
Volume 501,514